Lamivudine/tenofovir

From Wikipedia, the free encyclopedia

Lamivudine/tenofovir
Combination of
LamivudineNucleoside reverse transcriptase inhibitor
Tenofovir disoproxilNucleotide reverse transcriptase inhibitor
Clinical data
Trade namesCimduo, Temixys
AHFS/Drugs.comProfessional Drug Facts
MedlinePlusa618039
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
KEGG

Lamivudine/tenofovir disoproxil, sold under the brand name Cimduo or Temixys among others, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS in adults and children weighing more than 35 kilograms (77 lb).[1][2] It contains lamivudine and tenofovir disoproxil.[1] In the United States, it was approved by the Food and Drug Administration (FDA) in February 2018, for the treatment of HIV-1 infection.[1][3] It is taken by mouth.[1]

References[]

  1. ^ a b c d "Cimduo- lamivudine and tenofovir disoproxil fumarate tablet, film coated". DailyMed. 22 March 2018. Retrieved 26 March 2020.
  2. ^ Waters L, Mehta V, Gogtay J, Boffito M (March 2021). "The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV". Journal of Virus Eradication. 7 (1): 100028. doi:10.1016/j.jve.2021.100028. PMC 7868802. PMID 33598310.
  3. ^ "Drug Approval Package: Cimduo (lamivudine and tenofovir disoproxil fumarate)". U.S. Food and Drug Administration (FDA). 27 November 2018. Retrieved 26 March 2020.

Further reading[]

External links[]


Stub icon

This antiinfective drug article is a stub. You can help Wikipedia by .

  • v
  • t
Retrieved from ""